Screener
Indivior Pharmaceuticals, Inc. INDV Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued rebates and product returns | $551 | $582 |
| Accounts payable and accrued expenses | 178 | 250 |
| Accrued litigation settlement expenses, current | 14 | 42 |
| Current portion of long-term debt | — | 29 |
| Operating lease liabilities, current | 9 | 10 |
| Income taxes payable | 26 | 2 |
| Total current liabilities | 779 | 914 |
| Long-term debt, less current portion | 486 | 290 |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s current debt?
- Indivior Pharmaceuticals, Inc. (INDV) reported current debt of $0 in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s current debt changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s current debt decreased by 100.0% year-over-year, from $18M to $0.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s current debt?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc.'s current debt has grown at a 210.9% compound annual growth rate (CAGR), from $3M to $29M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Indivior Pharmaceuticals, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude